1. Home
  2. SBR vs GYRE Comparison

SBR vs GYRE Comparison

Compare SBR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBR
  • GYRE
  • Stock Information
  • Founded
  • SBR 1982
  • GYRE 2002
  • Country
  • SBR United States
  • GYRE United States
  • Employees
  • SBR N/A
  • GYRE N/A
  • Industry
  • SBR Oil & Gas Production
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • SBR Energy
  • GYRE Health Care
  • Exchange
  • SBR Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • SBR 941.4M
  • GYRE 990.4M
  • IPO Year
  • SBR N/A
  • GYRE N/A
  • Fundamental
  • Price
  • SBR $67.28
  • GYRE $9.07
  • Analyst Decision
  • SBR
  • GYRE
  • Analyst Count
  • SBR 0
  • GYRE 0
  • Target Price
  • SBR N/A
  • GYRE N/A
  • AVG Volume (30 Days)
  • SBR 38.7K
  • GYRE 178.7K
  • Earning Date
  • SBR 01-01-0001
  • GYRE 05-19-2025
  • Dividend Yield
  • SBR 7.96%
  • GYRE N/A
  • EPS Growth
  • SBR N/A
  • GYRE N/A
  • EPS
  • SBR 5.46
  • GYRE 0.05
  • Revenue
  • SBR $83,171,096.00
  • GYRE $105,757,000.00
  • Revenue This Year
  • SBR N/A
  • GYRE $22.01
  • Revenue Next Year
  • SBR N/A
  • GYRE $88.14
  • P/E Ratio
  • SBR $12.26
  • GYRE $189.70
  • Revenue Growth
  • SBR N/A
  • GYRE N/A
  • 52 Week Low
  • SBR $58.25
  • GYRE $6.11
  • 52 Week High
  • SBR $70.20
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • SBR 57.22
  • GYRE 52.76
  • Support Level
  • SBR $64.83
  • GYRE $7.03
  • Resistance Level
  • SBR $67.23
  • GYRE $9.51
  • Average True Range (ATR)
  • SBR 2.14
  • GYRE 0.87
  • MACD
  • SBR 0.42
  • GYRE 0.30
  • Stochastic Oscillator
  • SBR 98.81
  • GYRE 87.06

About SBR Sabine Royalty Trust

Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Share on Social Networks: